PAS Group gets $69.5 million takeover bid

Published 22-SEP-2015 14:06 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Private company Australia Brands Investment (ABI) has lobbed in a $69.5 million all-cash takeover bid for PAS Group (ASX: PGR), a price which is a 21% premium to its starting trading price today.

In a letter to PGR this morning, ABI said it would appoint Canaccord Genuity to buy up shares on market at 63c each, with either ABI or associated parties, being Coliseum Capital Management, already holding 19.23% of PGR’s shares.

ABI is giving PGR shareholders the opportunity to buy until 9 November, unless the offer period is extended.

At this stage there is no competing bid on the table, with ABI saying it is not inclined to raise the offer price.

So far there is evidence PGR shareholders are taking up the offer despite PGR management urging investors to take no action, with PGR shares skyrocketing by over 22% at the time of writing to 63.5c, above the offer price.

There has been heavy volume as well, with 7.3 million shares changing hands against a 30-day volume average of 73,600 shares.

ABI was set up by Coliseum Capital Management as a limited liability company, and is acting as a vehicle by which Coliseum can add to its 19.3% holding.

ABI said Coliseum was supportive of the board and its current direction, but was launching the bid simply to buy more shares in the fashion retailer.

The PGR Board is yet to respond to the takeover bid, but ABI said the Coliseum team and the PGR board had a “positive relationship”, and said Coliseum had in effect been doing due diligence on PGR for months before floating the bid and even before making the initial investment in PGR back in December last year.

ABI said Coliseum was keen to see PGR continue its investment in bricks and mortar retail, and pursue international brands with an eye towards expansion.

At the moment PGR has a stable of fashion brands under its purview, including Metalicus, Marco Polo, and White Runway.

However, it also licenses brands such as Slazenger, Everlast, Dunlop, and Disney.

During the 2015 financial year, PGR delivered a net profit after tax of $8.8 million from underlying earnings before interest and tax of $20.2 million.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free